Bona Releases 2021 Sustainability Report
5.4.2022 10:15:00 EEST | Business Wire | Press release
Bona ®, a global, sustainably-driven company that supplies products for installing, renovating, maintaining and restoring premium floors, today released the results of its 2021 Sustainability Report. The report highlights Bona’s most significant sustainability milestones for the year focused on its commitment to betterment for home, health, and humanity.
“Our commitment and responsible approach to the environment, people and society has remained steadfast for more than 100 years,” said Kerstin Lindell, Chair of the Board, Bona AB. “This past year presented some challenges, including supply chain and raw materials shortages, yet Bona stayed flexible and focused. Thanks to our fantastic team, our promise to deliver the best products and systems to our customers never wavered and we continue to identify more sustainable solutions. The ability to quickly shift, work together, and develop products and offerings despite changing market conditions has been key to our success.”
Sustainable development on the agenda
In 2021, Bona made some significant investments in its commitment to a sustainable future. The first was the introduction of an electric truck to Bona’s transportation fleet in Limburg, Germany. The electric truck will contribute to lower nitrogen dioxide levels in the city of Limburg and to global decarbonization. In Sweden, Bona invested in a geothermal system that will provide Bona’s Malmö facility with geothermal energy offsetting 20 percent of the yearly energy use at the facility. Another significant milestone last year was the purchase of 26,000-square-meters of land to build a new facility in Monroe, North Carolina, USA. The project, which will be completed in 2022, supports more efficient operations and increased internal capabilities allowing Bona US to operate in a more environmentally friendly way.
Björn Johansson Global Environmental Manager at Bona, said, “We continue to take important steps forward by increasing our use of renewable energy, smarter materials and packaging that uses less virgin plastic, and exhaustively researching new and better ingredients for our products. While we still have work to do, 2021 was a year where we made good progress.”
Highlights of the year
Bona’s core offering encourages care, maintenance, and renovation of hard flooring surfaces such as wood and resilient rather than replacing these materials thereby safeguarding the earth’s finite resources. In 2021 Bona produced finishes, stains, and sealers to cover more than 43 million square meters of wood flooring, saving a forest area equal to approximately 32 million square meters. By not cutting down the forest, the same number of trees encapsulates 28,917 tonnes of carbon dioxide (CO2), calculated as 9-ton CO by hectare and year.
Also in 2021, Bona initiated the use of 90 percent post-consumer recycled (PCR) material in its microfiber pads designed for the Bona Spray Mop and Bona Microfiber Mop. Aligning to the company’s goal to use less virgin plastic, this shift is helping divert over 217 tons of plastic waste from being incinerated or going to landfills.
In the autumn of last year, Bona received the Safer Choice Partner of the Year Award from the US Environmental Protection Agency (EPA) for its work innovating better ingredients in its floor cleaning solutions. Since becoming a Safer Choice partner in 2020, Bona has certified 13 products, six of which were certified in 2021.
Other key facts
Additional notable facts from Bona’s 2021 Sustainability report include:
- Five years ago, Bona moved its adhesive product from buckets to a tube packaging called “sausages.” In 2021 Bona reduced its environmental footprint by using sausages rather than buckets and over the past five years Bona has avoided using more than 258,000 buckets which is a carbon savings of 243,281 kg.
- An innovative ergonomic tool was launched 2021 as a new addition to the Bona FlexiSand Pro System. The Bona ErgoEdge is a machine attachment that allows flooring contractors to achieve smooth, efficient sanding in corners and edges of a floor without kneeling or bending by attaching to an existing, standing machine. This innovation saves time and offers a more ergonomic experience for the contractor all while providing a premium floor sanding experience.
- In 2021 Bona released several new products all of which were formulated with Bona’s commitment to greener chemistry including amplified formulas of its Bona Hardwood Floor and Bona Hard-Floor cleaning solutions. The formulations are water-based, biodegradable, meet the U.S. EPA product standards, and are Safer Choice Certified.
- Since 2016, Bona has collaborated with Hand in Hand, a non-governmental organization (NGO) that fights poverty with grassroots entrepreneurship, to increase the quality of life for three villages in India. With the organizations Village Upliftment Program, Bona’s partnership has helped improve living conditions for women and children through education and the creation of new jobs.
About the framework of Bona’s 2021 Sustainability Report
For the fifth year in a row, Bona reported the company's sustainability work in accordance with Swedish law and standards. The 2021 Sustainability Report aligns to the UN Sustainability goals and summarizes the sustainability information in the four areas of environment, social conditions, personnel and respect for human rights and the fight against corruption. View the full report at bona.com/sustainability
About Bona
Bona is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. Bona’s turnover is 3.1bn SEK (EUR 307 million) 2021. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 4 production units and 600 employees. For more visit www.bona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005107/en/
Contact information
Heather Lindemann | Bona
+1 (800) 872-5515
heather.lindemann@bona.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
